What the FDA labels say about taking them together
Nelfinavir and ticagrelor
Ticagrelor's FDA label of May 7, 2026 names nelfinavir in its drug interactions section; the nelfinavir label PlainMeds reads does not name ticagrelor. The ticagrelor label: “Avoid use of strong inhibitors of CYP3A.”
Check it at the source: the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the nelfinavir label say about ticagrelor?
Nelfinavir's label (effective December 11, 2025) does not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
What does the ticagrelor label say about nelfinavir?
Ticagrelor label, drug interactionsAvoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nelfinavir | Ticagrelor | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.253 per tablet 90 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once